Phase 3 IDEAL Study Supports Livdelzi Effect on ALP Normalization in PBC
FROM THE WIRE · FINANCE.YAHOO.COM
- Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67× ULN, Despite Receiving UDCA or with Intolerance to UDCA - - Gilead Will Engage Global Regulatory Authorities…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive clinical data on a Gilead drug that may support its commercial outlook.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Phase 3 IDEAL study shows most patients reached ALP normalization.
- 02Data will be presented at The Liver Meeting.
- 03Gilead will engage global regulatory authorities based on these results.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Gilead Sciences, Inc.171.10 USD-2.44%today -1.94%Positive Gilead Sciences Inc78.90 BRLMarket closedtoday -1.19%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets